COVID-19 and the Promise of Small Molecule Therapeutics: Are There Lessons to Be Learnt?

Overview

Journal Pharmacol Res

Publisher Elsevier

Specialty Pharmacology

Date 2022 Apr 3

PMID 35367622

Authors

Wei Shen Ho

Ruirui Zhang

Yeong Lan Tan

Christina Li Lin Chai

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic had grounded the world to a standstill. As the disease continues to rage two years on, it is apparent that effective therapeutics are critical for a successful endemic living with COVID-19. A dearth in suitable antivirals has prompted researchers and healthcare professionals to investigate existing and developmental drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although some of these drugs initially appeared to be promising for the treatment of COVID-19, they were ultimately found to be ineffective. In this review, we provide a retrospective analysis on the merits and limitations of some of these drugs that were tested against SARS-CoV-2 as well as those used for adjuvant therapy. While many of these drugs are no longer part of our arsenal for the treatment of COVID-19, important lessons can be learnt. The recent inclusion of molnupiravir and Paxlovid™ as treatment options for COVID-19 represent our best hope to date for endemic living with COVID-19. Our viewpoints on these two drugs and their prospects as current and future antiviral agents will also be provided.

Citing Articles

The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2.

Huang R, Warner Jenkins G, Kim Y, Stanfield R, Singh A, Martinez-Yamout M Proc Natl Acad Sci U S A. 2023; 120(39):e2303455120.

PMID: 37722054 PMC: 10523490. DOI: 10.1073/pnas.2303455120.

The Interplay among Glucocorticoid Therapy, Platelet-Activating Factor and Endocannabinoid Release Influences the Inflammatory Response to COVID-19.

de Carvalho J, da Silva-Neto P, Toro D, Fuzo C, Nardini V, Pimentel V Viruses. 2023; 15(2).

PMID: 36851787 PMC: 9959303. DOI: 10.3390/v15020573.

Monkeypox epidemic at the door: should we remain idly by or prepare strongly?.

Al-Kuraishy H, Al-Gareeb A, Hetta H, Alexiou A, Papadakis M, El-Saber Batiha G AMB Express. 2023; 13(1):5.

PMID: 36637577 PMC: 9837758. DOI: 10.1186/s13568-023-01507-0.

A sustainable synthesis of the SARS-CoV-2 M inhibitor nirmatrelvir, the active ingredient in Paxlovid.

Kincaid J, Caravez J, Iyer K, Kavthe R, Fleck N, Aue D Commun Chem. 2022; 5(1):156.

PMID: 36465589 PMC: 9685088. DOI: 10.1038/s42004-022-00758-5.

Deuterated Drugs and Biomarkers in the COVID-19 Pandemic.

Jansen-van Vuuren R, Jedlovcnik L, Kosmrlj J, Massey T, Derdau V ACS Omega. 2022; 7(46):41840-41858.

PMID: 36440130 PMC: 9685803. DOI: 10.1021/acsomega.2c04160.

References

Pedersen N, Perron M, Bannasch M, Montgomery E, Murakami E, Liepnieks M . Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. J Feline Med Surg. 2019; 21(4):271-281. PMC: 6435921. DOI: 10.1177/1098612X19825701. View

Grant O, Montgomery D, Ito K, Woods R . Analysis of the SARS-CoV-2 spike protein glycan shield reveals implications for immune recognition. Sci Rep. 2020; 10(1):14991. PMC: 7490396. DOI: 10.1038/s41598-020-71748-7. View

Khandia R, Singhal S, Alqahtani T, Kamal M, El-Shall N, Nainu F . Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic. Environ Res. 2022; 209:112816. PMC: 8798788. DOI: 10.1016/j.envres.2022.112816. View

Padhi A, Shukla R, Saudagar P, Tripathi T . High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance. iScience. 2021; 24(1):101992. PMC: 7807151. DOI: 10.1016/j.isci.2020.101992. View

Murphy B, Perron M, Murakami E, Bauer K, Park Y, Eckstrand C . The nucleoside analog GS-441524 strongly inhibits feline infectious peritonitis (FIP) virus in tissue culture and experimental cat infection studies. Vet Microbiol. 2018; 219:226-233. PMC: 7117434. DOI: 10.1016/j.vetmic.2018.04.026. View

Sorrell F, Szklarz M, Abdul Azeez K, Elkins J, Knapp S . Family-wide Structural Analysis of Human Numb-Associated Protein Kinases. Structure. 2016; 24(3):401-11. PMC: 4780864. DOI: 10.1016/j.str.2015.12.015. View

Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P . Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002; 346(26):2039-46. DOI: 10.1056/NEJMoa012354. View

Horby P, Lim W, Emberson J, Mafham M, Bell J, Linsell L . Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med. 2020; 384(8):693-704. PMC: 7383595. DOI: 10.1056/NEJMoa2021436. View

Pan H, Peto R, Henao-Restrepo A, Preziosi M, Sathiyamoorthy V, Abdool Karim Q . Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results. N Engl J Med. 2020; 384(6):497-511. PMC: 7727327. DOI: 10.1056/NEJMoa2023184. View

10.

Lu R, Zhao X, Li J, Niu P, Yang B, Wu H . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224):565-574. PMC: 7159086. DOI: 10.1016/S0140-6736(20)30251-8. View

11.

Choy K, Wong A, Kaewpreedee P, Sia S, Chen D, Hui K . Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. Antiviral Res. 2020; 178:104786. PMC: 7127386. DOI: 10.1016/j.antiviral.2020.104786. View

12.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

13.

Campbell W . Ivermectin as an antiparasitic agent for use in humans. Annu Rev Microbiol. 1991; 45:445-74. DOI: 10.1146/annurev.mi.45.100191.002305. View

14.

Spinner C, Gottlieb R, Criner G, Lopez J, Cattelan A, Soriano Viladomiu A . Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2020; 324(11):1048-1057. PMC: 7442954. DOI: 10.1001/jama.2020.16349. View

15.

Zhou S, Hill C, Sarkar S, Tse L, Woodburn B, Schinazi R . β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. J Infect Dis. 2021; 224(3):415-419. PMC: 8136050. DOI: 10.1093/infdis/jiab247. View

16.

Chaudhuri S, Symons J, Deval J . Innovation and trends in the development and approval of antiviral medicines: 1987-2017 and beyond. Antiviral Res. 2018; 155:76-88. PMC: 7126013. DOI: 10.1016/j.antiviral.2018.05.005. View

17.

Shannon A, Le N, Selisko B, Eydoux C, Alvarez K, Guillemot J . Remdesivir and SARS-CoV-2: Structural requirements at both nsp12 RdRp and nsp14 Exonuclease active-sites. Antiviral Res. 2020; 178:104793. PMC: 7151495. DOI: 10.1016/j.antiviral.2020.104793. View

18.

Gomes C, Fernandes D, Casimiro F, da Mata G, Passos M, Varela P . Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics. Front Cell Infect Microbiol. 2020; 10:589505. PMC: 7753008. DOI: 10.3389/fcimb.2020.589505. View

19.

Yu Y, Briggs K, Taraban M, Brinson R, Marino J . Grand Challenges in Pharmaceutical Research Series: Ridding the Cold Chain for Biologics. Pharm Res. 2021; 38(1):3-7. PMC: 7869771. DOI: 10.1007/s11095-021-03008-w. View

20.

Kabinger F, Stiller C, Schmitzova J, Dienemann C, Kokic G, Hillen H . Mechanism of molnupiravir-induced SARS-CoV-2 mutagenesis. Nat Struct Mol Biol. 2021; 28(9):740-746. PMC: 8437801. DOI: 10.1038/s41594-021-00651-0. View